Abstract

Body Mass Index (BMI) is a crucial determinant of nutritional status and overall health, particularly impactful in individuals facing concurrent diagnoses of leukemia and HIV/AIDS. This review examines the intricate relationship between BMI variations and quality of life (QoL) in leukemia patients living with HIV, aiming to elucidate the multifaceted mechanisms underlying their interconnectedness. Through an extensive synthesis of existing literature, this review provides insights into how BMI fluctuations influence not only metabolic health and immune function but also psychosocial well-being, ultimately shaping QoL outcomes in this vulnerable patient population. Leukemia and HIV/AIDS represent significant health challenges individually, with their coexistence posing unique clinical complexities. BMI emerges as a tangible indicator of nutritional status, reflecting metabolic imbalances and nutritional deficiencies prevalent in leukemia patients living with HIV. Maintaining optimal BMI levels assumes paramount importance in supporting immune function, enhancing treatment responses, and mitigating treatment-related toxicities, all of which are integral to improving QoL outcomes. BMI variations exert profound effects on treatment responses and clinical outcomes in leukemia patients living with HIV. Low BMI is associated with heightened treatment-related morbidity and mortality, as well as diminished treatment efficacy. Conversely, elevated BMI may confer resistance to certain therapies and increase the risk of metabolic complications, further impacting QoL and treatment outcomes. Understanding these dynamics is essential for tailoring therapeutic strategies to optimize QoL and enhance overall well-being in this vulnerable patient population